BRPI0510691A - marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento - Google Patents
marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamentoInfo
- Publication number
- BRPI0510691A BRPI0510691A BRPI0510691-5A BRPI0510691A BRPI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- present
- haplotype
- determine response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
MARCADORES DE HAPLóTIPOS E MéTODOS DE USO DOS MESMOS PARA DETERMINAR RESPOSTA AO TRATAMENTO. A presente invenção relaciona-se a métodos para diagnóstico ou previsão da capacidade de resposta ao tratamento, como Alefacept, por determinação da presença de um nucleotídeo em um ou mais sítios polimórficos em um marcador de haplótipo. A presente invenção identifica múltiplos haplótipos que estão associados à resposta a Alefacept. Os marcadores de haplótipo identificados pela presente invenção e métodos da invenção podem ser particularmente úteis para o diagnóstico ou previsão da suscetibilidade a doenças da pele, como Psoríase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56837104P | 2004-05-04 | 2004-05-04 | |
PCT/US2005/015531 WO2005112568A2 (en) | 2004-05-04 | 2005-05-04 | Haplotype markers and methods of using the same to determine response to treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0510691A true BRPI0510691A (pt) | 2007-12-26 |
Family
ID=35428732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0510691-5A BRPI0510691A (pt) | 2004-05-04 | 2005-05-04 | marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080020383A1 (pt) |
EP (1) | EP1747291A2 (pt) |
KR (1) | KR20070011558A (pt) |
CN (1) | CN1997756A (pt) |
BR (1) | BRPI0510691A (pt) |
CA (1) | CA2565804A1 (pt) |
IL (1) | IL178970A0 (pt) |
MX (1) | MXPA06012744A (pt) |
WO (1) | WO2005112568A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2149612A1 (en) * | 2008-07-29 | 2010-02-03 | Merck Serono SA | Genetic markers of response to efalizumab |
GB2467161A (en) | 2009-01-26 | 2010-07-28 | Sharp Kk | Nitride nanoparticles |
GB2467162A (en) | 2009-01-26 | 2010-07-28 | Sharp Kk | Fabrication of nitride nanoparticles |
LT2462246T (lt) * | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
US9370449B2 (en) | 2014-02-26 | 2016-06-21 | Luma Therapeutics, Inc. | Phototherapy dressing for treating psoriasis |
US20190168016A1 (en) | 2016-02-09 | 2019-06-06 | Luma Therapeutics, Inc. | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
CN114085873A (zh) * | 2021-11-16 | 2022-02-25 | 珠海中科先进技术研究院有限公司 | 一种癌细胞状态辨识基因电路组及其制备方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579844A (en) * | 1976-05-13 | 1986-04-01 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5047336A (en) * | 1985-10-30 | 1991-09-10 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides |
JPH0763830B2 (ja) * | 1985-11-26 | 1995-07-12 | アスモ株式会社 | ダイカスト鋳造金型への離型剤塗布方法 |
US5190859A (en) * | 1987-02-26 | 1993-03-02 | Dana-Farber Cancer Institute, Inc. | Purification of LFA-3 |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5185441A (en) * | 1988-08-26 | 1993-02-09 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3 |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5122514A (en) * | 1990-04-23 | 1992-06-16 | Abbott Laboratories | Psoriasis treatment |
CA2081028C (en) * | 1991-03-12 | 1999-12-14 | Barbara P. Wallner | Cd2 binding domain of lymphocyte function associated antigen 3 |
MX9203138A (es) * | 1991-03-12 | 1992-09-01 | Biogen Inc | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. |
AU660312B2 (en) * | 1991-06-06 | 1995-06-22 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same |
US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
NZ298712A (en) * | 1995-01-16 | 1998-12-23 | Commw Scient Ind Res Org | Fatty acid acyl group conjugates as therapeutic compounds |
ES2252999T3 (es) * | 1998-08-31 | 2006-05-16 | Biogen Idec Ma Inc. | Modulacion de celulas t efectoras y de memoria con un ligando de cd2. |
US6337337B1 (en) * | 1998-09-03 | 2002-01-08 | Carol J. Buck | Methods for treating disorders responsive to DHFR-inhibition |
WO2002060480A1 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Methods for treating or preventing skin disorders using cd2-binding agents |
WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
-
2005
- 2005-05-04 US US11/578,342 patent/US20080020383A1/en not_active Abandoned
- 2005-05-04 KR KR1020067025262A patent/KR20070011558A/ko not_active Application Discontinuation
- 2005-05-04 CA CA002565804A patent/CA2565804A1/en not_active Abandoned
- 2005-05-04 EP EP05779971A patent/EP1747291A2/en not_active Withdrawn
- 2005-05-04 MX MXPA06012744A patent/MXPA06012744A/es unknown
- 2005-05-04 BR BRPI0510691-5A patent/BRPI0510691A/pt not_active IP Right Cessation
- 2005-05-04 WO PCT/US2005/015531 patent/WO2005112568A2/en active Application Filing
- 2005-05-04 CN CNA2005800213929A patent/CN1997756A/zh active Pending
-
2006
- 2006-10-31 IL IL178970A patent/IL178970A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20080020383A1 (en) | 2008-01-24 |
EP1747291A2 (en) | 2007-01-31 |
CN1997756A (zh) | 2007-07-11 |
IL178970A0 (en) | 2007-03-08 |
WO2005112568A3 (en) | 2006-05-11 |
CA2565804A1 (en) | 2005-12-01 |
KR20070011558A (ko) | 2007-01-24 |
WO2005112568A2 (en) | 2005-12-01 |
MXPA06012744A (es) | 2007-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0510691A (pt) | marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento | |
Ikeda et al. | HLA class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions | |
James et al. | Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum | |
EA200970578A1 (ru) | Генетические маркеры для предотвращения риска аритмии сердца | |
EA200971079A1 (ru) | ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ | |
EP4293358A3 (en) | Volatile organic compounds as cancer biomarkers | |
BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
BRPI0710436A8 (pt) | método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga | |
WO2008069975A3 (en) | Methods of using f-spondin as a biomarker for cartilage degenerative conditions | |
BRPI0416355A (pt) | métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss | |
WO2007092433A3 (en) | Osteoporosis associated markers and methods of use thereof | |
BRPI0908425B8 (pt) | métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3 | |
BRPI0712225A8 (pt) | métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r | |
WO2012018535A3 (en) | Wellness panel | |
WO2008132763A3 (en) | Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction | |
EP2637020A3 (en) | Predictive markers for ovarian cancer | |
BR0308161A (pt) | métodos para a detecção de distúrbios genéticos | |
BRPI0718322A2 (pt) | Métodos para diagnosticar uma suscetibilidade para câncer em um indivíduo humano, para identificar um marcador para o uso na avaliação da suscetibilidade para câncer, para genotipar uma amostra de ácido nucléico, para avaliar um inidivíduo quanto a probabilidade de resposta a um agente terapêutico, para predizer o prognóstico e para monitorar o progresso de um tratamento de um indivíduo, kit para avaliar a suscetibilidade para câncer em um indivíduo, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para câncer em um indivíduo. | |
WO2006091776A3 (en) | Biomarkers for predicting prostate cancer progression | |
BR112013013457A2 (pt) | métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições | |
WO2010036960A8 (en) | Methods for treating, diagnosing, and monitoring lupus | |
ATE476525T1 (de) | Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern | |
BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
Munir et al. | The association of 9p21-3 locus with coronary atherosclerosis: a systematic review and meta-analysis | |
WO2010054195A3 (en) | Markers and methods for assessing and treating lupus patients susceptible to photoprovocation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |